EP4105214A4 - Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak - Google Patents

Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak Download PDF

Info

Publication number
EP4105214A4
EP4105214A4 EP20919255.8A EP20919255A EP4105214A4 EP 4105214 A4 EP4105214 A4 EP 4105214A4 EP 20919255 A EP20919255 A EP 20919255A EP 4105214 A4 EP4105214 A4 EP 4105214A4
Authority
EP
European Patent Office
Prior art keywords
jak
drugs
preparation
related diseases
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20919255.8A
Other languages
German (de)
English (en)
Other versions
EP4105214A1 (fr
Inventor
Shuai WANG
Degang Wang
Shouting WU
Tingting Yu
Miao FANG
Liwei MU
Liang Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of EP4105214A1 publication Critical patent/EP4105214A1/fr
Publication of EP4105214A4 publication Critical patent/EP4105214A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP20919255.8A 2020-02-13 2020-02-13 Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak Pending EP4105214A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/075024 WO2021159372A1 (fr) 2020-02-13 2020-02-13 Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak

Publications (2)

Publication Number Publication Date
EP4105214A1 EP4105214A1 (fr) 2022-12-21
EP4105214A4 true EP4105214A4 (fr) 2023-11-08

Family

ID=77292614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20919255.8A Pending EP4105214A4 (fr) 2020-02-13 2020-02-13 Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak

Country Status (8)

Country Link
US (1) US20230113620A1 (fr)
EP (1) EP4105214A4 (fr)
JP (1) JP7395762B2 (fr)
KR (1) KR20220127900A (fr)
CN (1) CN115066425B (fr)
AU (1) AU2020428591B2 (fr)
CA (1) CA3169832A1 (fr)
WO (1) WO2021159372A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4108664A4 (fr) * 2020-02-21 2024-03-06 Zhuhai United Laboratories Co., Ltd. Forme cristalline d'inhibiteur de jak et son application
KR20230129248A (ko) * 2021-01-29 2023-09-07 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 억제제 또는 이의 염 또는 결정형을 함유하는 경구제제, 및 이의 제조 방법 및 응용

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010187A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220688A1 (en) 2005-07-27 2009-09-03 Buddy Tools, Llc Drywall tape and joint compound dispenser
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP3492469B1 (fr) * 2016-07-26 2021-12-01 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Composé en tant qu'inhibiteur sélectif jak, son sel et son utilisation thérapeutique
CA2939286A1 (fr) * 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclique contenant des composes et usages pharmaceutiques dudit spirocyclique
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
KR102603729B1 (ko) * 2018-08-23 2023-11-17 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010187A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires

Also Published As

Publication number Publication date
JP7395762B2 (ja) 2023-12-11
WO2021159372A1 (fr) 2021-08-19
CN115066425B (zh) 2023-06-23
CA3169832A1 (fr) 2021-08-19
AU2020428591A1 (en) 2022-08-25
CN115066425A (zh) 2022-09-16
JP2023513599A (ja) 2023-03-31
US20230113620A1 (en) 2023-04-13
KR20220127900A (ko) 2022-09-20
AU2020428591B2 (en) 2024-05-23
EP4105214A1 (fr) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112016008016B8 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
EP4062914A4 (fr) Utilisation d'un inhibiteur de fak dans la préparation d'un médicament pour le traitement de tumeurs présentant une mutation nras
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2017013275A (es) Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
DK2544674T3 (da) Cdc7-kinaseinhibitorer og anvendelser deraf
EP3976010A4 (fr) Oligonucléotides et leurs méthodes d'utilisation pour traiter des affections neurologiques
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EP4105214A4 (fr) Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak
EP3915985A4 (fr) Dérivé de pyrrolopyridine et son utilisation dans la prévention et le traitement d'une maladie liée à la protéine kinase
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
EP3988542A4 (fr) Dérivé de pyrimidine inhibant la croissance d'une cellule cancéreuse et son utilisation médicinale
EP3941551A4 (fr) Administration sous-cutanée de nanoparticules comprenant un inhibiteur de mtor et une albumine pour le traitement de maladies
EP4241781A4 (fr) Utilisation d'un inhibiteur de p55pik dans la préparation d'un médicament destiné au traitement de la maladie de la sècheresse oculaire
EP3549596A4 (fr) Utilisation de microcystines dans la préparation de médicaments pour la prévention ou le traitement de maladies de fibrose d'organe et de tissu
EP3888692A4 (fr) Inhibiteur de protéine interagissant avec la striatine et son utilisation dans la préparation d'un médicament anti-tumoral
EP3766503A4 (fr) Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires
IN2009DN06586A (fr)
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP4013401A4 (fr) Articles et modes d'administration d'agents thérapeutiques
EP3957310A4 (fr) Composition et son utilisation dans la préparation d'un médicament destiné au traitement d'un cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231009

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/438 20060101ALI20231002BHEP

Ipc: A61P 37/08 20060101ALI20231002BHEP

Ipc: A61P 37/06 20060101ALI20231002BHEP

Ipc: A61P 17/06 20060101ALI20231002BHEP

Ipc: A61P 19/02 20060101ALI20231002BHEP

Ipc: A61K 31/437 20060101ALI20231002BHEP

Ipc: C07D 471/04 20060101AFI20231002BHEP